October 22, 2025

FDA Redefining Depression Treatment with New Approvals?

Researchers analyze FDA-approved and Phase 3 antidepressants from 2009 to 2025.

Conexiant

October 17, 2025

FDA Awards Nine CNPV Vouchers to Speed Reviews

Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration.

Conexiant

October 16, 2025

HHS Memo: Fringe Finds a Footing

From wheat fields to Washington: a decades-old fear about skies and 'sprays' rises again, colliding with science, social media, and the machinery of federal policymaking.

KFF Health News

October 16, 2025

Depression Risk Rises Among Gabapentin Users

Gabapentin is most strongly associated with depression among women, lower-income patients, and those who sleep fewer than 7 hours per night.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 10, 2025

FDA Broadens Label for Schizophrenia Drug

The FDA has approved a new long-acting injectable treatment option for adults with bipolar I disorder.

Conexiant

September 26, 2025

Old Medicine, New Hope for Speech?

Leucovorin, a folic acid–derived drug, is under study for speech benefits in children with autism.

KFF Health News

May 28, 2024

Former Doc Accused of Murder-for-Hire, Sentenced for Distribution

Former doctor sentenced to 90 months in federal prison for illegal opioid distribution and health care fraud.

Conexiant

April 29, 2024

Record Heat Waves Propel Surge in Heat-Related Illness

2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.

Conexiant